Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Publikationen
Suchbegriffe: NAB-PACLITAXEL, . Treffer: 7
2022
Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K
Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645
Doi: 10.1055/a-1548-4847
Web of Science
PubMed
FullText
FullText_MUG
2021
Pichler, M; Steyrer, J
Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1.
ESMO Open. 2021; 6(4): 100198
Doi: 10.1016/j.esmoop.2021.100198
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Prager, GW; Oehler, L; Gerger, A; Mlineritsch, B; Andel, J; Petzer, A; Wilthoner, K; Sliwa, T; Pichler, P; Winder, T; Heibl, S; Gruenberger, B; Laengle, F; Hubmann, E; Korger, M; Pecherstorfer, M; Djanani, A; Neumann, HJ; Philipp-Abbrederis, K; Wöll, E; Trondl, R; Arnold-Schrauf, C; Eisterer, W
Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Eur J Cancer. 2021; 143:101-112
Doi: 10.1016/j.ejca.2020.11.003
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, DA; Rossmann, CH; Stotz, M; Schaberl-Moser, R; Pichler, M; Stöger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Eur J Cancer. 2021; 151: 3-13.
Doi: 10.1016/j.ejca.2021.03.040
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2020
Riedl, JM; Posch, F; Prager, G; Eisterer, W; Oehler, L; Sliwa, T; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Neumann, HJ; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Laengle, F; Wöll, E; Gerger, A
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.
Ther Adv Med Oncol. 2020; 12: 1758835919900872-1758835919900872.
Doi: 10.1177/1758835919900872
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2019
Scheithauer, W; Putora, PM; Grünberger, B; Eisterer, W; Wöll, E; Prager, G; Schaberl-Moser, R; Greil, R; Glatzer, M
Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.
Therap Adv Gastroenterol. 2019; 12(5):1756284819877635-1756284819877635
Doi: 10.1177/1756284819877635
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
2016
Czink, E; Heining, C; Weber, TF; Lasitschka, F; Schemmer, P; Schirmacher, P; Weiss, KH; Glimm, H; Brors, B; Weichert, W; Jäger, D; Fröhling, S; Springfeld, C
[Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer].
Z Gastroenterol. 2016; 54(5):426-430
Doi: 10.1055/s-0042-103498
Web of Science
PubMed
FullText
FullText_MUG